Where Science meets Business

The Tech Park Basel is the premier address for early-stage tech start-ups in Basel. It offers a collaboration-friendly, yet business-driven environment and is part of the rapidly growing Stücki Park in the dynamic northern part of Basel. The Tech Park Basel provides office space and fully equipped laboratories at highly favorable terms, and offers shared facilities and a variety of other services to tech start-ups.

About us

Offering

Infrastructure

Tech Park Basel offers modern office space and fully equipped, state-of-the-art laboratories at favorable conditions.

More Information

Services

Tech Park Basel provides various comprehensive services for your convenience and on your journey to business success.

More Information

Meeting Rooms

Benefit from various meeting rooms and services for your convenience, including organising events and promoting knowledge transfer.

More Information

Community

Join a modern and diverse collaboration- and business-friendly environment in a vibrant and inclusive community of a thriving environment.

More Information

Workspace designed for people to innovate, connect and thrive.

We run the infrastructure so you can run your organisation.

LEARN MORE

News

Versameb Strengthens its Board of Directors

by Tech Park Basel

Significant appointments of experienced drug development and financial experts – Hernán Levett, Dr Lily Geidelberg, Paul Korner, MD, MBA and Dr Alexandre LeBeaut...

Cellestia Biotech announces the Initiation of Phase II Trial for the treatment of rr/r-T-ALL patients is now open for recruitment

by Tech Park Basel

The Investigator Initiated Phase II Trial at MD Anderson Cancer Center combining CB-103 and Venetoclax for the treatment of rr/r-T-ALL patients is now open for recruitment...

BioVersys announces first patient dosed in Phase 2a clinical trial with BVL-GSK098

by Tech Park Basel

31.01.2023
BioVersys AG announces first patient dosed in Phase 2a clinical trial with BVL-GSK099, to investigate a new treatment concept to address multidrug-resistance tuberculosis...

BioVersys extends its series C round to CHF 32.6 Million

by Administrator

05.01.2023
BioVersys AG announces extension of its Series C investment round to CHF 32.6 million as the AMR Action Fund makes its first European-based investment...

New Tech Park Basel CEO selected

by Tech Park Basel

26.10.2022
We are pleased to announce that Christian Harr (current COO) will become the new CEO of Tech Park Basel. He will take up the new position on...

Industry Night 2022: Tech Park Basel draws a positive conclusion

by Tech Park Basel

23.09.2022
Impressive first edition: The Regio Basel 2022 Industry Night was also a great success at Tech Park Basel. 44 companies from Basel and the region opened their ...

Kinarus announces the issuance of convertible notes

by Tech Park Basel

22.08.2022
Kinarus announces the issuance of convertible notes of up to CHF 20 million to an entity managed by Yorkville...

Versant Ventures Launches Vector BioPharma AG

by Tech Park Basel

10.08.2022
Versant has made a $30 million Series A commitment to Vector, which is the most recent company to be launched out of the ...

Cellestia ’s CB-103 in achieving complete response

by Administrator

22.06.2022
A case study shows contribution of Cellestia ’s CB-103 in achieving complete response in a relapse/refractor T-ALL patient...

BIOVERSYS SUCCESSFULLY COMPLETES PHASE I CLINICAL TRIALS OF BVL-GSK098

by Tech Park Basel

21.06.2022
BioVersys AG announces successful completion of Phase I clinical trials with BVL-GSK098...

BIOVERSYS ANNOUNCES CHF 24.2 MILLION FINANCING

by Tech Park Basel

08.06.2022
BioVersys AG announces successful first closing of CHF 24.2 million Series C financing to develop clinical pipeline of novel AMR...

Versant Ventures Launches Cimeio Therapeutics with $50 Million Series A

by Tech Park Basel

29.04.2022
Versant Ventures announced the debut of Cimeio Therapeutics, a biotechnology company developing a novel approach to ...

Ginkgo Bioworks Signs Definitive Agreement to Acquire FGen AG

by Tech Park Basel

18.03.2022
Ginkgo Bioworks, the leading horizontal platform for cell programming, today announced the entry into a definitive agreement to acquire...

Anaveon To Raise CHF 110 Million In Oversubscribed Series B Financing

by Tech Park Basel

21.12.2021
Anaveon, a clinical-stage immuno-oncology company, today announced that it has agreed a CHF 110 million Series B financing led...

Cellestia Biotech receives Orphan Drug Designation from EU Commision

by Tech Park Basel

16.12.2021
Cellestia Biotech AG (Cellestia) is a fully integrated R&D company specialised in the discovery and development of first-in-class...

Kinarus receives 7 Million CHF Grant

by Tech Park Basel

14.12.2021
Kinarus AG has been awarded a grant from the Swiss Federal Funding Programme for the development of COVID-19 Medicines...

Versameb to present novel data on its lead asset

by Tech Park Basel

04.11.2021

Versameb to present novel data on its lead asset, VMB-100 at 9th International mRNA Health Conference...

Kinarus Secures CHF 57 Million Capital Commitment

by Tech Park Basel

14.09.2021
Kinarus AG, a clinical-stage Swiss biopharmaceutical company, announced today that it has signed an agreement with...

TargImmune successfully closed its 2021 financing round

by Tech Park Basel

27.07.2021
TargImmune Therapeutics AG (Basel, Switzerland), a privately held Swiss-based biotechnology company focused on ...

Monte Rosa Therapeutics raises USD 222 million in successful IPO

by Tech Park Basel

29.06.2021
Monte Rosa Therapeutics, a US-Swiss biotech company focused on discovering and developing precision medicines that degrade disease-causing proteins, reached...

Alentis Therapeutics Raises USD 67 Million in Series B Financing

by Tech Park Basel

15.06.2021
Basel, Switzerland and Strasbourg, France, 15 June 2021 — Alentis Therapeutics, the Swiss biotech developing breakthrough treatments for fibrotic diseases, today announced that it has raised USD67 (CHF60) million in a Series B financing round.

Virtual Auditorium Talk: ‘How to attract and retain best talents for Life Sciences startups’

by Tech Park Basel

14.06.2021
The Technologiepark Basel and the Swiss Biotech Association invite you to a virtual talk about: ‘How to attract and retain best talents for Life Sciences startups’.

BIOVERSYS receives CARB-X Award of up to US$ 15.34 Mio.

by Administrator

02.06.2021
CARB-X funds BioVersys up to US$ 15.34 million to further develop pyrrolocytosines, a novel class of broad-spectrum antibiotics, targeting difficult to treat ESKAPE pathogens

Kinarus presents plans for a drug against Long Covid

by Tech Park Basel

31.05.2021
Kinarus is working on a drug against Covid-19, which is also intended to combat typical Long Covid symptoms. The medicament is aimed to be launched on the market in 2022.

We are hiring an additional female Board Member

by Tech Park Basel

11.05.2021
Der Tech Park Basel wurde über die letzten zehn Jahre im Stücki Park im Norden von Basel auf- und ausgebaut. Heute bietet er auf rund 6'700 m2 für über 30 innovative, technologieorientierte Start-ups ein inspirierendes Umfeld und verleiht der Wirtschaft im Kanton Basel- Stadt wichtige Impulse.

POLYNEURON AWARDED GRANT OF CHF 1.2M

by Tech Park Basel

05.05.2021
Polyneuron Pharmaceuticals AG, a clinical-stage developer of a new class of antigen-specific polymers for the treatment of patients with serious autoimmune diseases, today announced that the company and collaborators at the University of Basel have received a grant from the Swiss Innovation Agency Innosuisse to support a project valued at CHF 1.2 million.